Endocrinology

Latest News


CME Content


Empagliflozin Reduces Liver Fat in Early Diabetes

Researchers writing in Diabetes Care this month report that empagliflozin, a sodium–glucose cotransporter 2 inhibitor (SGLT2), successfully reduced liver fat content in recent-onset and metabolically well-controlled type 2 diabetes (T2D).